In patients with NSCLC, over 50% of BRAF mutations are non-V600 mutations, and real-world studies have shown that some patients with non-V600 BRAF mutations can also benefit from targeted therapy.130. This evidence concerns the gene BRAF and non-small cell lung carcinoma.